

LRIG1 Blocking Peptide (C-term)
Synthetic peptide
Catalog # BP19769b**Specification**

LRIG1 Blocking Peptide (C-term) - Product Information

Primary Accession [O96JA1](#)
Other Accession [P70193](#), [NP_056356.2](#)

LRIG1 Blocking Peptide (C-term) - Additional Information

Gene ID 26018

Other Names

Leucine-rich repeats and immunoglobulin-like domains protein 1, LIG-1, LRIG1, LIG1

Target/Specificity

The synthetic peptide sequence is selected from aa 816-829 of HUMAN LRIG1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LRIG1 Blocking Peptide (C-term) - Protein Information

Name LRIG1 {ECO:0000303|PubMed:15282549}

Synonyms LIG1

Function

Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location

Widely expressed..

LRIG1 Blocking Peptide (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

LRIG1 Blocking Peptide (C-term) - Images

LRIG1 Blocking Peptide (C-term) - Background

LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.

LRIG1 Blocking Peptide (C-term) - References

Rose, J. Phd, et al. Mol. Med. (2010) In press :
Ye, F., et al. J. Neurooncol. 94(2):183-194(2009)
Ljuslinder, I., et al. Breast Cancer Res. 11 (3), 403 (2009) :
Miller, J.K., et al. Cancer Res. 68(20):8286-8294(2008)
Stutz, M.A., et al. Oncogene 27(43):5741-5752(2008)